Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E, Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and the ODYSSEY-trial teamPublished in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th,...
Results from the Odyssey trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections in Boston, USA.
Authors: Moore CL, Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial TeamPublished in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34 Download
Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial TeamPublished in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22 Download
Authors: Bollen P, Turkova A, Mujuru H, et al. for the ODYSSEY Trial Team Published in: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_830 Download
Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail TeamPublished in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019 Download
Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A, White I, and ODYSSEY trial teamPublished in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019 Download
Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...
ODYSSEY has reached a major milestone by completing the recruitment of participants to the main trial. A big thank you to all the sites and everyone else for their hard work and continuous effort put into making the study a success.
We are pleased to report that a presentation from the ODYSSEY team at MRC CTU at UCL was well received at the 40th Annual Conference of the International Society for Clinical Biostatistics in Leuven, Belgium (14 – 18 July 2019). Rebecca Turner delivered the talk as part of the Bayesian clinical trials session on Tuesday morning (16 July).